These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3285227)

  • 21. Delay of the initiation of hypertension in spontaneously hypertensive rats by CV-4151, a specific thromboxane A2 synthetase inhibitor.
    Shibouta Y; Terashita Z; Inada Y; Nishikawa K
    Eur J Pharmacol; 1985 Feb; 109(2):135-44. PubMed ID: 3922775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase].
    Nakazawa M; Iizuka K; Ujiie A; Hiraku S; Ohki S
    Yakugaku Zasshi; 1994 Dec; 114(12):911-33. PubMed ID: 7869235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.
    Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C
    J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prior inhibition of vasoconstrictors normalizes GFR in postobstructed kidneys.
    Purkerson ML; Klahr S
    Kidney Int; 1989 Jun; 35(6):1305-14. PubMed ID: 2549296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of thromboxane synthetase inhibitors on cyclical reduction of coronary blood flow in dogs.
    Uchida Y; Murao S
    Jpn Heart J; 1981 Nov; 22(6):971-5. PubMed ID: 7040725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
    Yoshida T; Kameda H; Ichikawa Y; Tojo T; Homma M
    J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboxane A2 synthase inhibitors. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acids.
    Johnson RA; Nidy EG; Aiken JW; Crittenden NJ; Gorman RR
    J Med Chem; 1986 Aug; 29(8):1461-8. PubMed ID: 3735314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis.
    Remuzzi G; Imberti L; Rossini M; Morelli C; Carminati C; Cattaneo GM; Bertani T
    J Clin Invest; 1985 Jan; 75(1):94-101. PubMed ID: 4038407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of eicosanoid mediation of the renal functional effects of hyperchloremia.
    Askari B; Bell-Quilley CP; Fulton D; Quilley J; McGiff JC
    J Pharmacol Exp Ther; 1997 Jul; 282(1):101-7. PubMed ID: 9223545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake.
    Rodríguez F; Llinás MT; González JD; Rivera J; Salazar FJ
    Hypertension; 2000 Aug; 36(2):276-81. PubMed ID: 10948090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of thromboxane synthetase inhibitors on the action of bronchoactive agents and on arachidonate metabolism in the guinea pig tracheobronchopulmonary system].
    Kitamura S; Ishihara Y; Takaku F
    Nihon Kyobu Shikkan Gakkai Zasshi; 1984 Jan; 22(1):3-8. PubMed ID: 6539836
    [No Abstract]   [Full Text] [Related]  

  • 35. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A.
    Perico N; Benigni A; Zoja C; Delaini F; Remuzzi G
    Am J Physiol; 1986 Oct; 251(4 Pt 2):F581-7. PubMed ID: 3094383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
    Edmonds LC; Lefer AM
    Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury.
    Masumura H; Kunitada S; Irie K; Ashida S; Abe Y
    Eur J Pharmacol; 1991 Feb; 193(3):321-7. PubMed ID: 2055246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of SA-446, an angiotensin-converting enzyme inhibitor, on renal function in anesthetized dogs: special reference to arachidonic acid metabolites.
    Miura K; Yukimura T; Imanishi M; Okahara T; Abe Y; Yamamoto K
    J Cardiovasc Pharmacol; 1985; 7(1):102-7. PubMed ID: 2580127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboxane synthesis and blood pressure in spontaneously hypertensive rats.
    Purkerson ML; Martin KJ; Yates J; Kissane JM; Klahr S
    Hypertension; 1986 Dec; 8(12):1113-20. PubMed ID: 3793195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.